Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is not only the front-runner in China’s innovative medicine, but also a well-known R&D base of antineoplastics and surgical medicine in China. Taking the slogan that “Technology as the basis, and innovative healthy life”，Hengrui Medicine is dedicated to research, developing, and promoting innovative medicine with high quality. We aim to help doctors solve clinical problems, help patients be cured, and help improve the standard of health for all humanity. Hengrui Medicine focuses on fulfilling the unmet clinical demands, promoting innovation in technology, and serving the health of humanity. Hengrui Medicine invests 10% of its annual turnovers in research and development, and has constituted a thorough innovation system with R&D centers and clinic departments in New Jersey, Shanghai, Chengdu, and Lianyungang.
The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. The diversification of products, comprehensive product lines, and the pursuit of innovation endow us with great competitive advantage. Hengrui Medicine is committed to producing high quality medicines to help more patients have access to better and affordable medical resources more timely. Adhering to the highest level of the US FDA management standards to manage the production, Hengrui Medicine is the first pharmaceutical enterprise that sells domestic injection doses overseas to Europe, US, and Japan. By taking global coordination, we have been creating more value for our patients and stake holders, and curbed the rapid increase of global health care cost. Hengrui Medicine now produces and sells injection doses, oral dosages, and many other types of medicine in the EU and US markets. No matter it is in cities or rural areas, we are more accessible to patients, clinicians, and business partners.